256 Newsroom — Uganda's Digital News Infrastructure
Business

Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial - Fierce Biotech

Published by FierceBiotech By Darren Incorvaia · 5 September 2026 at 04:18
Share
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial - Fierce Biotech
Image · FierceBiotech

What the report says

Novartis’ Ionis-partnered drug designed to lower levels of Lp(a), a known cardiovascular risk factor,

Read the full report at FierceBiotech →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

Uganda, Nigeria Seek Stronger Business Ties Under AfCFTASoftPower News 256 Newsroom Uganda, Nigeria pledge to seal delayed cooperation pact as Kampala trade forum opens - PML DailyPML Daily 256 Newsroom Police investigate attempted murder of Mbarara businesswoman - Daily MonitorDaily Monitor 256 Newsroom How Uganda's Betting Market Compares to the US Boom - Daily MonitorDaily Monitor UDB-Supported Enterprises Create, Sustain 69,202 Jobs- ReportNile Post Why your electronic signature is rejected by URSBThe Independent Uganda